Fate Therapeutics, Inc., CRISPR Therapeutics AG, M&T Bank Corp made today's list of top gainers.

Markets closed higher today; Dow Jones closed the day at 34,000, having gained 0.3%. S&P 500 gained 0.33% and closed at 4,151.32.

More data out today as United States TIC Net Long-Term Transactions (Feb) released today at 20:00 UTC with a figure of 71 billion, while the previous figure was 31.9 billion.

Today was an exciting day for markets with several stocks capitalising on the risk-on mood. Have a look at these Top Gainers:

M&T Bank gains 7.78%, closes at $125.66 ahead of the quarterly earnings report set for today

M&T Bank rallied 7.78% and ended the session at $125.66. M&T Bank is currently trading with a market cap of $21.12 billion with an average daily volume of 2.33 million shares. So far this year, it has been doing worse than the S&P by 27.16%.

M&T Bank is scheduled to announce earnings results today. The consensus EPS estimate is 3.98 and the consensus revenue estimate is $2.39 billion.

Enphase Energy | Closed +7.67% at $224.92

After ending Friday at $208.9, Enphase Energy rallied to $229.23 today, hitting its highest point in 5 weeks. It later lost $4.31 and closed at $224.92. Having set a significant high of $336 4 months ago, the energy technology company is trading 37.83% lower. So far this year, it has been under-performing the S&P by 25.11%. Enphase Energy's market cap is currently $30.81 billion with an average daily volume of 3.52 million shares.

CRISPR Therapeutics | Up 7.91% to $54.29 today

CRISPR Therapeutics gained $3.98 and closed above the $51 level for the first time in 6 weeks. Over the past 8 months, the Swiss biotechnology company has retreated 39.95% from a noteworthy peak of $83.78. So far this year, it has been beating the Nasdaq by 8.39%. The company is currently trading with a market cap of $4.27 billion with an average daily volume of 1.19 million shares. CRISPR Therapeutics is forecasted to generate revenues of $1.62 million and EPS of $-2.32.

Fate Therapeutics | Up 9.65% to $6.59 today

The cellular immunotherapy developer topped out at $6.66 having ended today at $6.59. However, despite early momentum, the stock gave up its gains to now trade at $6.59.